{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(4)"],"submitter":["Noh CK"],"pubmed_abstract":["The long-term effect of <i>Helicobacter pylori</i> eradication on metachronous gastric neoplasm prevention after endoscopic submucosal dissection (ESD) of gastric adenoma is unclear. This study included patients with confirmed <i>H. pylori</i> infection after ESD with curative resection for gastric adenoma. Patients were divided based on the success of <i>H. pylori</i> eradication treatment into two groups: eradication and non-eradication. Patients with any newly detected lesion within 1 year after ESD and recurrence at the ESD site were excluded from the analysis. Further, 1:1 propensity score matching was also performed to eliminate baseline differences between the two groups. <i>H. pylori</i> eradication treatment was administered to 673 patients after ESD (163 in the successful eradication group and 510 in the non-eradication group). During the median follow-up periods of 25 and 39 months in the eradication and non-eradication groups, metachronous gastric neoplasm was identified in 6 (3.7%) and 22 patients (4.3%), respectively. Adjusted Cox analysis revealed that <i>H. pylori</i> eradication was not associated with increased risk of metachronous gastric neoplasm after ESD. Kaplan-Meier analysis in the matched population yielded similar findings (<i>p</i> = 0.546). <i>H. pylori</i> eradication treatment was not associated with metachronous gastric neoplasm after ESD with curative resection for gastric adenoma."],"journal":["Journal of clinical medicine"],"pagination":["1512"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9962017"],"repository":["biostudies-literature"],"pubmed_title":["Effect of <i>Helicobacter pylori</i> Eradication Treatment on Metachronous Gastric Neoplasm Prevention Following Endoscopic Submucosal Dissection for Gastric Adenoma."],"pmcid":["PMC9962017"],"pubmed_authors":["Noh CK","Lee KM","Lee GH","Shin SJ","Park B","Lim SG","Lee E"],"additional_accession":[]},"is_claimable":false,"name":"Effect of <i>Helicobacter pylori</i> Eradication Treatment on Metachronous Gastric Neoplasm Prevention Following Endoscopic Submucosal Dissection for Gastric Adenoma.","description":"The long-term effect of <i>Helicobacter pylori</i> eradication on metachronous gastric neoplasm prevention after endoscopic submucosal dissection (ESD) of gastric adenoma is unclear. This study included patients with confirmed <i>H. pylori</i> infection after ESD with curative resection for gastric adenoma. Patients were divided based on the success of <i>H. pylori</i> eradication treatment into two groups: eradication and non-eradication. Patients with any newly detected lesion within 1 year after ESD and recurrence at the ESD site were excluded from the analysis. Further, 1:1 propensity score matching was also performed to eliminate baseline differences between the two groups. <i>H. pylori</i> eradication treatment was administered to 673 patients after ESD (163 in the successful eradication group and 510 in the non-eradication group). During the median follow-up periods of 25 and 39 months in the eradication and non-eradication groups, metachronous gastric neoplasm was identified in 6 (3.7%) and 22 patients (4.3%), respectively. Adjusted Cox analysis revealed that <i>H. pylori</i> eradication was not associated with increased risk of metachronous gastric neoplasm after ESD. Kaplan-Meier analysis in the matched population yielded similar findings (<i>p</i> = 0.546). <i>H. pylori</i> eradication treatment was not associated with metachronous gastric neoplasm after ESD with curative resection for gastric adenoma.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-08-17T03:05:25.324Z","creation":"2025-04-06T09:35:02.374Z"},"accession":"S-EPMC9962017","cross_references":{"pubmed":["36836045"],"doi":["10.3390/jcm12041512"]}}